Skip to main content

Clamp Study

0
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

GEROPHARM
GEROPHARMRussia - Moscow
5 programs
GP-40081N/A1 trial
Insulin AspartN/A1 trial
Insulin LisproN/A1 trial
Insulin Lispro Mix 25N/A1 trial
RinGlar®N/A1 trial
Active Trials
NCT04184492Completed34Est. Jun 2019
NCT04184466Completed26Est. Dec 2018
NCT03604575Completed28Est. Dec 2016
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GEROPHARMGP-40081
GEROPHARMInsulin Aspart
GEROPHARMRinGlar®
GEROPHARMInsulin Lispro Mix 25
GEROPHARMInsulin Lispro

Clinical Trials (5)

Total enrollment: 178 patients across 5 trials

A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

Start: Apr 2019Est. completion: Jun 201934 patients
N/ACompleted
NCT04184466GEROPHARMInsulin Aspart

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects

Start: Oct 2018Est. completion: Dec 201826 patients
N/ACompleted

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Start: Oct 2017Est. completion: Feb 201842 patients
N/ACompleted
NCT03606018GEROPHARMInsulin Lispro Mix 25

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects

Start: Apr 2017Est. completion: Jul 201748 patients
N/ACompleted
NCT03604575GEROPHARMInsulin Lispro

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects

Start: Aug 2016Est. completion: Dec 201628 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.